Condition: End Stage Renal Disease · Sponsor: Vanderbilt University Medical Center
Frailty and sarcopenia are modifiable risk factors for morbidity and mortality in patients with ESRD. Exercise is the recommended intervention to prevent frailty and sarcopenia, however, many clinical trials have shown limited clinical improvement in muscle mass and physical function. We propose that mitochondrial dysfunction is one of the deterrents to the effectiveness of the exercise. We plan to evaluate the additive effect of HIIT and CoQ10, a mitochondrial-targeted therapy, on mitochondrial function and physical performance. Understanding the interplay among CoQ10, exercise, and mitochondrial function will identify novel mechanisms to improve the efficiency of exercise. This will also serve to prevent frailty, sarcopenia, and muscle dysfunction in patients with ESRD.
This description comes directly from the study's public registry record.
Delia M Woods, BSN/MSL · 615-322-1749 · delia.woods@vumc.org
Patricia Wright, BSN · 615-322-8837 · patricia.wright@vumc.org
Always discuss trial participation with your own doctor first.
| University of California Davis Health | Sacramento, California, United States | Not Yet Recruiting |
| Vanderbilt University Medical Center-GCRC | Nashville, Tennessee, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05422534